Ospedale Regionale di Lugano

Running trials

• Recruiting

  Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.

  NCT06776172· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Source

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Source

• Recruiting

  Surgery for Recurrent Glioblastoma

  NCT02394626· Phase 2· Source

• Active, not recruiting

  Ischaemic PReconditioning In Non Cardiac surgEry

  NCT02427867· Source

• Enrolling by invitation

  Juvenile Inflammatory Rheumatism (JIR) Cohorte

  NCT02377245· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Glioblastoma1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

  NCT05798520· Phase 2· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.

  NCT04760990· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source